1. A 44-year-old woman receives alteplase for acute ischemic stroke. Her physician explains that systemic plasmin generation is normally limited by an endogenous inhibitor that rapidly inactivates any plasmin that escapes into the circulation. Loss of this inhibitor's capacity — as occurs when it is consumed during thrombolytic therapy — allows systemic plasminemia to develop. Which of the following correctly identifies this inhibitor and its mechanism?
A) PAI-1 (plasminogen activator inhibitor-1), a serine protease inhibitor secreted by endothelial cells and platelets that neutralizes circulating plasmin by forming a covalent inhibitory complex with its active site
B) Antithrombin III, a serine protease inhibitor that neutralizes both thrombin and plasmin by forming 1:1 stoichiometric complexes, with its activity accelerated 1,000-fold by heparin binding
C) Alpha-2-antiplasmin, a serine protease inhibitor that circulates in plasma and rapidly forms a covalent 1:1 complex with free plasmin, inactivating it within milliseconds; when plasmin is fibrin-bound, alpha-2-antiplasmin access is sterically hindered, which is why fibrinolysis proceeds at the clot surface but not in the circulation
D) Thrombomodulin, an endothelial surface receptor that binds thrombin and diverts it toward activation of protein C, which then indirectly inhibits plasmin by degrading the cofactors needed for plasminogen activation
E) TAFI (thrombin-activatable fibrinolysis inhibitor), a carboxypeptidase activated by the thrombin-thrombomodulin complex that removes C-terminal lysine residues from fibrin, reducing plasminogen binding sites and attenuating fibrinolysis
ANSWER: C
Rationale:
Option C is correct. Alpha-2-antiplasmin (α2-AP) is the primary physiological inhibitor of plasmin in the circulation. It is a serine protease inhibitor (serpin) that forms a rapid, irreversible covalent 1:1 complex with free plasmin, inactivating it within milliseconds of its appearance in plasma. The key mechanistic nuance is steric: when plasmin is bound to fibrin within a clot (via its kringle domains engaging fibrin lysine residues), alpha-2-antiplasmin cannot access the plasmin active site efficiently, permitting fibrinolysis to proceed locally. Free plasmin released into the systemic circulation is rapidly neutralized. During thrombolytic therapy, massive plasmin generation overwhelms alpha-2-antiplasmin capacity, consuming it and allowing systemic plasminemia — which degrades circulating fibrinogen, factor V, and factor VIII.
Option A: Option A is incorrect: PAI-1 is the primary inhibitor of tPA and uPA (plasminogen activators), not of plasmin itself; PAI-1 prevents plasminogen activation but does not directly neutralize formed plasmin.
Option B: Option B is incorrect: antithrombin III neutralizes thrombin, factor Xa, IXa, XIa, and XIIa — it does not inhibit plasmin; antithrombin has no direct anti-plasmin activity.
Option D: Option D is incorrect: thrombomodulin-thrombin complexes activate protein C, which inactivates factors Va and VIIIa (anticoagulant effect) — this has no direct relationship to plasmin inhibition.
Option E: Option E is incorrect: TAFI does attenuate fibrinolysis by removing plasminogen-binding lysine residues from fibrin, but it is not the primary circulating plasmin inhibitor; it modulates the rate of fibrinolysis rather than acutely neutralizing free plasmin in circulation.
2. A cardiologist is choosing between alteplase and streptokinase for a patient with acute STEMI (ST-segment elevation myocardial infarction). She notes that the coronary thrombus is platelet-rich and that platelet activation releases high local concentrations of PAI-1 (plasminogen activator inhibitor-1). Which of the following best explains the pharmacological relevance of local PAI-1 concentration to this clinical choice, and why engineered fibrin-specific agents are preferred in this environment?
A) PAI-1 is the primary endogenous inhibitor of tPA (tissue plasminogen activator) and uPA (urokinase plasminogen activator); high PAI-1 concentrations at platelet-rich arterial thrombi inhibit fibrin-specific agents such as alteplase by neutralizing free tPA before it can bind fibrin-bound plasminogen; tenecteplase addresses this directly through its engineered 14-fold greater PAI-1 resistance compared with native tPA, making it less susceptible to inhibition in the high-PAI-1 microenvironment of an arterial thrombus
B) PAI-1 directly inhibits plasmin by forming covalent complexes with its active site serine residue; fibrin-specific agents are preferred because their fibrin-binding concentrates plasmin activity at the clot surface where PAI-1 concentrations are paradoxically lowest, away from the platelet-dense core
C) PAI-1 activates streptokinase by inducing a conformational change in the streptokinase-plasminogen activator complex, causing it to generate plasmin indiscriminately; fibrin-specific agents are not affected because they do not form complexes with plasminogen in the presence of PAI-1
D) PAI-1 competes with fibrinogen for plasmin binding, displacing plasmin from the fibrin surface and releasing it into the systemic circulation; fibrin-specific agents are preferred because their high fibrin affinity prevents this displacement even at high PAI-1 concentrations
E) PAI-1 accelerates the natural rate of plasminogen activation by tPA in the absence of fibrin, causing paradoxical systemic fibrinogenolysis; fibrin-specific agents are preferred because their fibrin-dependence prevents PAI-1-driven off-target plasmin generation in the circulation
ANSWER: A
Rationale:
Option A is correct. PAI-1 (plasminogen activator inhibitor-1) is the principal endogenous inhibitor of both tPA and uPA — it forms a rapid, covalent 1:1 inhibitory complex with these serine proteases, neutralizing their plasminogen-activating capacity. At the site of arterial thrombosis, platelet activation and degranulation release PAI-1 stored in platelet alpha-granules, creating a high-PAI-1 microenvironment within and around the platelet-rich thrombus. This local PAI-1 enrichment can significantly blunt the thrombolytic efficacy of tPA-based agents by neutralizing free (non-fibrin-bound) tPA. Tenecteplase was engineered with the KHRR(296–299)AAAA substitution specifically to increase PAI-1 resistance 14-fold over native tPA, improving its ability to sustain plasminogen activation in this hostile environment.
Option B: Option B is incorrect: PAI-1 inhibits plasminogen activators (tPA, uPA), not plasmin itself — the primary plasmin inhibitor is alpha-2-antiplasmin; the claim that PAI-1 forms covalent complexes with plasmin's active site serine is mechanistically wrong.
Option C: Option C is incorrect: PAI-1 does not activate streptokinase; streptokinase forms its activator complex with plasminogen through an entirely PAI-1-independent mechanism.
Option D: Option D is incorrect: PAI-1 does not compete with fibrinogen for plasmin binding; it inhibits tPA and uPA upstream of plasmin generation and has no direct interaction with plasmin's fibrin-binding kringle domains.
Option E: Option E is incorrect: PAI-1 inhibits (not accelerates) tPA activity; in the absence of fibrin, PAI-1 suppresses tPA-driven plasminogen activation — it does not paradoxically accelerate it.
3. A resident asks why tenecteplase can be administered as a single IV bolus for STEMI (ST-segment elevation myocardial infarction) while alteplase requires a 90-minute weight-based infusion for the same indication. Which of the following correctly identifies the structural modification responsible for tenecteplase's prolonged half-life and explains how it enables single-bolus administration?
A) Tenecteplase contains an additional kringle domain not present in native tPA that binds fibrin with higher affinity, slowing its dissociation from the thrombus surface and reducing the rate of hepatic uptake, thereby extending its effective duration of action
B) Tenecteplase is pegylated (conjugated with polyethylene glycol chains) at its N-terminus, which sterically blocks hepatic clearance receptors and extends the plasma half-life from approximately 4 minutes to over 2 hours, permitting single-bolus dosing
C) Tenecteplase has a substitution in its protease domain that eliminates its fibrin-binding capacity, causing it to circulate freely rather than being rapidly extracted by hepatic fibronectin receptors; the reduced hepatic clearance extends its half-life sufficiently for single-bolus use
D) Tenecteplase's longer half-life results from its non-fibrin-specific mechanism — because it activates circulating rather than fibrin-bound plasminogen, it is not rapidly consumed at the clot surface and therefore remains active in plasma much longer than fibrin-bound agents
E) Tenecteplase carries T103N and N117Q substitutions that introduce N-linked glycosylation sites in the kringle-1 domain, reducing hepatic clearance via the mannose receptor pathway and extending the plasma half-life to approximately 20 to 24 minutes compared with approximately 4 to 6 minutes for alteplase; this longer half-life supports a single weight-based IV bolus (30 to 50 mg by body weight) rather than a prolonged infusion
ANSWER: E
Rationale:
Option E is correct. Native tPA (alteplase) is cleared rapidly from plasma primarily by hepatic receptors (including the mannose receptor and LRP — low-density lipoprotein receptor-related protein), giving it a plasma half-life of approximately 4 to 6 minutes. This rapid clearance necessitates continuous infusion to maintain therapeutic plasma concentrations throughout clot dissolution. Tenecteplase carries two amino acid substitutions — T103N and N117Q — in the kringle-1 domain that introduce new N-linked glycosylation sites. These additional carbohydrate chains sterically hinder recognition by hepatic clearance receptors, reducing hepatic uptake and extending the plasma half-life to approximately 20 to 24 minutes. A third substitution (KHRR→AAAA in the protease domain) confers PAI-1 resistance but does not contribute to the extended half-life. The combination of prolonged half-life and single-bolus dosing makes tenecteplase particularly practical for prehospital administration and community hospital settings.
Option A: Option A is incorrect: tenecteplase does not contain an additional kringle domain; it shares the same domain structure as alteplase (finger, EGF, kringle-1, kringle-2, and protease domains) — the modifications are point substitutions, not domain additions.
Option B: Option B is incorrect: tenecteplase is not pegylated; PEGylation is a modification used for some biologics (such as PEG-filgrastim) but not for any approved thrombolytic agent.
Option C: Option C is incorrect: tenecteplase retains fibrin-binding capacity and is more fibrin-specific than alteplase, not less; loss of fibrin binding would be clinically counterproductive and is not the mechanism of its extended half-life.
Option D: Option D is incorrect: tenecteplase is a fibrin-specific agent, not a non-fibrin-specific one; streptokinase activates free circulating plasminogen (non-specific) but has a half-life determined by its own clearance kinetics, not by this mechanism.
4. A clinical pharmacist is orienting a new resident to the thrombolytic agents available in the hospital formulary for STEMI (ST-segment elevation myocardial infarction). The resident asks about reteplase. Which of the following correctly distinguishes reteplase from alteplase in terms of dosing regimen, weight adjustment, and approved indications?
A) Reteplase is administered as a single 50 mg IV bolus over 5 seconds, adjusted to body weight in 10-kg increments; it is approved for STEMI and acute ischemic stroke, offering a weight-based alternative to alteplase's fixed 100 mg PE dose
B) Reteplase is administered as two fixed 10-unit IV boluses given 30 minutes apart, with no weight-based dose adjustment; it is approved for STEMI only in the United States and is non-inferior to alteplase for coronary reperfusion, but unlike tenecteplase it is not approved for acute ischemic stroke or pulmonary embolism
C) Reteplase is administered as a continuous IV infusion of 0.5 units/kg/hr titrated to aPTT (activated partial thromboplastin time), making it the only weight-based thrombolytic used for STEMI; its approved indications match those of alteplase including stroke and PE
D) Reteplase is administered as a single 10-unit IV bolus with a second 10-unit bolus given only if ST resolution is less than 50% at 90 minutes; the conditional second dose distinguishes it from other dual-bolus protocols and allows dose reduction in patients with prior hemorrhagic risk factors
E) Reteplase is a recombinant streptokinase derivative administered as two 750,000-unit boluses 30 minutes apart; unlike streptokinase it is non-antigenic because its streptokinase component has been humanized, and it is approved for STEMI and submassive PE
ANSWER: B
Rationale:
Option B is correct. Reteplase (r-PA) is a deletion mutant of tPA that retains its protease and kringle-2 domains but lacks the finger, EGF, and kringle-1 domains present in alteplase; this deletion reduces fibrin affinity but permits renal clearance and a longer half-life of approximately 13 to 16 minutes compared with alteplase's 4 to 6 minutes. Its approved dosing regimen is two fixed 10-unit IV boluses given 30 minutes apart, with no body weight adjustment — a significant practical advantage over alteplase's weight-based 90-minute infusion in STEMI. The GUSTO-III trial demonstrated non-inferiority to alteplase for 30-day mortality in STEMI. Reteplase is approved in the United States for STEMI only — it is not approved for acute ischemic stroke or pulmonary embolism, unlike alteplase.
Option A: Option A is incorrect: the single weight-based bolus description (50 mg, 10-kg increments) describes tenecteplase, not reteplase; reteplase uses two fixed 10-unit boluses and is not approved for stroke.
Option C: Option C is incorrect: reteplase is not given as a continuous infusion or weight-based drip; the infusion-with-aPTT monitoring description applies to UFH adjunctive therapy, not the thrombolytic itself.
Option D: Option D is incorrect: the reteplase protocol is both 10-unit boluses unconditionally — there is no conditional second dose based on ST resolution; the two-bolus regimen is the complete standard protocol regardless of early reperfusion signs.
Option E: Option E is incorrect: reteplase is a deletion mutant of human tPA, not a streptokinase derivative; it is non-antigenic because it is recombinant human protein, not because streptokinase has been humanized — streptokinase is a completely different molecule with no structural relationship to tPA.
5. A 70-year-old man arrives in the emergency department with acute ischemic stroke symptoms and a last known well time of 2 hours ago. His initial BP (blood pressure) is 196/104 mmHg. The team wants to administer alteplase. Which of the following correctly states the BP thresholds that must be met before alteplase administration and maintained after it, and identifies the recommended agents for achieving these targets?
A) BP must be reduced to below 160/90 mmHg before alteplase and maintained below 140/90 mmHg for 48 hours after administration; labetalol IV or hydralazine IV are the recommended agents for intravenous BP reduction in this setting
B) BP must be reduced to below 220/120 mmHg before alteplase — there is no mandatory BP threshold for the 0 to 3 hour window; after administration, BP must be maintained below 160/100 mmHg for 24 hours using any available antihypertensive
C) No specific BP threshold is required before alteplase in acute ischemic stroke as long as the patient is not in hypertensive emergency (BP above 220/120 mmHg); post-administration BP management is guided by neurological examination rather than a fixed threshold
D) BP must be reduced to and maintained below 185/110 mmHg before alteplase administration; after administration, BP must be maintained below 180/105 mmHg for at least 24 hours to reduce the risk of hemorrhagic transformation; recommended IV agents for pre-treatment BP reduction include labetalol IV (10 to 20 mg boluses) or nicardipine IV infusion
E) BP must be reduced to below 150/90 mmHg before alteplase to minimize hemorrhagic transformation risk; this aggressive pre-treatment target is associated with improved 90-day functional outcomes in the ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) trial
ANSWER: D
Rationale:
Option D is correct. Current AHA/ASA guidelines specify that BP must be at or below 185/110 mmHg at the time of alteplase administration and must be maintained below 180/105 mmHg for at least 24 hours afterward to reduce the risk of hemorrhagic transformation of the ischemic infarct. This patient's BP of 196/104 mmHg exceeds the pre-treatment threshold, so BP must be lowered before alteplase can be given — typically with labetalol IV (10 to 20 mg IV over 1 to 2 minutes, may repeat once) or a nicardipine IV infusion (5 mg/hr, titrated up to 15 mg/hr). If BP cannot be lowered to and maintained at or below 185/110 mmHg, alteplase should not be administered. Post-treatment BP control below 180/105 mmHg for 24 hours is equally important to protect the ischemic territory from hemorrhagic conversion.
Option A: Option A is incorrect: the 160/90 mmHg pre-treatment threshold and 140/90 mmHg post-treatment target are below the guideline thresholds; overly aggressive BP reduction in acute ischemic stroke can reduce cerebral perfusion pressure in the ischemic penumbra and worsen neurological outcomes.
Option B: Option B is incorrect: there is a mandatory BP threshold even in the 0 to 3 hour window — the 185/110 mmHg ceiling applies to all time windows; the claim that there is no mandatory threshold in the first 3 hours is incorrect.
Option C: Option C is incorrect: there is a specific and mandatory BP threshold (185/110 mmHg) before alteplase, and post-administration management is defined by a fixed target (180/105 mmHg), not solely by neurological examination.
Option E: Option E is incorrect: the ENCHANTED trial evaluated intensive BP lowering (target systolic 130 to 140 mmHg) after alteplase and found it did not improve functional outcome and increased early neurological deterioration; targeting below 150/90 mmHg pre-treatment is not guideline-supported and conflicts with the established 185/110 mmHg threshold.
6. A 62-year-old man with massive PE (pulmonary embolism) is hemodynamically unstable (systolic BP 78 mmHg). The team is ready to administer alteplase. During the rapid contraindication screen, a nurse notes the patient had an ischemic stroke 10 weeks ago with near-complete neurological recovery. Which of the following correctly classifies this finding and its implications for thrombolytic therapy?
A) Ischemic stroke 10 weeks ago is a relative contraindication for PE thrombolysis; because the patient has had near-complete neurological recovery and the PE indication is life-threatening, the risk-benefit ratio favors proceeding with alteplase at the standard 100 mg dose
B) Ischemic stroke 10 weeks ago is relevant only for the stroke thrombolysis indication; for STEMI and PE thrombolysis, only prior intracranial hemorrhage (not prior ischemic stroke) constitutes an absolute contraindication, so alteplase may be administered without restriction
C) Ischemic stroke within the preceding 3 months is an absolute contraindication to fibrinolytic therapy in both STEMI and PE, because prior ischemic stroke markedly increases the risk of hemorrhagic transformation of the infarcted territory during systemic thrombolysis; this patient's stroke 10 weeks ago falls within the 3-month window and alteplase must not be administered
D) Ischemic stroke within 3 months is an absolute contraindication only within the first 6 weeks; at 10 weeks the prohibition has lapsed and alteplase may be given for life-threatening PE, though with heightened monitoring for neurological deterioration
E) Prior ischemic stroke at any time is a permanent absolute contraindication to all fibrinolytic therapy regardless of recovery, in the same category as prior intracranial hemorrhage; once a patient has had an ischemic stroke they are never eligible for thrombolysis for any indication
ANSWER: C
Rationale:
Option C is correct. For thrombolysis in STEMI and PE, ischemic stroke within the preceding 3 months is listed as an absolute contraindication in major guidelines (AHA/ACC for STEMI; AHA/ASA and CHEST for PE). The rationale is that prior ischemic infarction creates a zone of blood-brain barrier disruption, neovascularization, and impaired autoregulation that markedly increases the risk of hemorrhagic transformation when systemic plasminemia develops during thrombolysis. Ten weeks equals approximately 70 days — which falls within the 3-month (approximately 90-day) prohibition window. Alteplase must not be administered for this patient's PE. The clinical team should urgently consider catheter-directed embolectomy, surgical embolectomy, or extracorporeal membrane oxygenation (ECMO) as alternative reperfusion strategies.
Option A: Option A is incorrect: ischemic stroke within 3 months is an absolute contraindication for PE thrombolysis in current guidelines, not a relative one; the life-threatening nature of the PE does not convert an absolute contraindication into a relative one in established guideline language.
Option B: Option B is incorrect: prior ischemic stroke within 3 months is explicitly listed as an absolute contraindication for both STEMI and PE fibrinolysis — not only for stroke fibrinolysis; distinguishing ischemic stroke as irrelevant for STEMI/PE contraindications is factually incorrect.
Option D: Option D is incorrect: there is no guideline-defined 6-week lapsing point within the 3-month prohibition; the 3-month window is the established cutoff, and 10 weeks is within it.
Option E: Option E is incorrect: prior ischemic stroke is not a permanent lifetime contraindication; it is contraindicated only within the preceding 3 months — a patient who had an ischemic stroke more than 3 months ago and has recovered is not permanently excluded from fibrinolysis for other indications (though each case still requires careful individualized risk-benefit assessment).
7. A 55-year-old woman is actively bleeding after thrombolytic therapy for acute ischemic stroke. Her fibrinogen level is 74 mg/dL. The blood bank asks whether she needs cryoprecipitate or FFP (fresh frozen plasma) for fibrinogen replacement. Which of the following correctly compares the fibrinogen content per unit volume of these two products and explains why cryoprecipitate is the preferred product for targeted fibrinogen replacement in this setting?
A) Cryoprecipitate contains fibrinogen at approximately 15 to 30 mg/mL per unit (approximately 150 to 250 mg total fibrinogen per unit in a volume of approximately 15 to 30 mL), whereas FFP contains fibrinogen at approximately 2 to 3 mg/mL per unit (approximately 400 to 600 mg total in approximately 200 to 250 mL); achieving equivalent fibrinogen replacement with FFP requires transfusing 4 to 6 units (approximately 1,000 to 1,500 mL total volume), creating substantial fluid overload risk that makes cryoprecipitate the volume-efficient choice
B) Cryoprecipitate and FFP contain equivalent fibrinogen concentrations per mL; the clinical preference for cryoprecipitate is based on its additional content of factor XIII, which crosslinks fibrin polymers and is specifically depleted by thrombolytic therapy, making fibrin clot stabilization the primary rationale for its use
C) FFP contains higher concentrations of fibrinogen per unit than cryoprecipitate because FFP preserves the full plasma protein content without the cold-precipitation step that partially degrades fibrinogen; the preference for cryoprecipitate is therefore based on cost and availability rather than concentration advantage
D) Cryoprecipitate is preferred over FFP solely because it can be administered without ABO (blood group) compatibility matching, reducing preparation time in emergent bleeding; the fibrinogen concentrations in the two products are similar per unit administered
E) Cryoprecipitate contains recombinant fibrinogen concentrate rather than donor-derived fibrinogen, eliminating transfusion-transmitted infection risk; FFP contains native plasma fibrinogen but carries higher infectious risk, making cryoprecipitate the safer choice independent of concentration differences
ANSWER: A
Rationale:
Option A is correct. The concentration difference between cryoprecipitate and FFP is the pharmacological rationale for preferring cryoprecipitate for targeted fibrinogen replacement. Cryoprecipitate is prepared by thawing FFP at 1 to 6°C and collecting the cold-insoluble precipitate, which concentrates fibrinogen, factor VIII, factor XIII, vWF (von Willebrand factor), and fibronectin into a small volume (approximately 15 to 30 mL per unit). Each unit contains approximately 150 to 250 mg fibrinogen, giving a concentration of approximately 15 to 30 mg/mL. FFP, by contrast, contains fibrinogen at the normal plasma concentration of approximately 2 to 3 mg/mL; a single FFP unit of 200 to 250 mL contains approximately 400 to 600 mg of fibrinogen — more total fibrinogen per unit by mass, but requiring a much larger volume. For a patient needing 50 to 70 mg/dL of fibrinogen increase, 10 units of cryoprecipitate (approximately 150 to 300 mL total) achieves this; the equivalent correction with FFP would require 4 to 6 units (approximately 1,000 to 1,500 mL), with substantial fluid overload and TRALI (transfusion-related acute lung injury) risk.
Option B: Option B is incorrect: cryoprecipitate and FFP do not contain equivalent fibrinogen concentrations — cryoprecipitate is approximately 5 to 10 times more concentrated per mL; factor XIII content is an additional benefit of cryoprecipitate but is not the primary rationale for its selection in fibrinogen replacement.
Option C: Option C is incorrect: the cold-precipitation step concentrates fibrinogen rather than degrading it — FFP contains lower fibrinogen concentration per mL than cryoprecipitate, not higher; the preference for cryoprecipitate is based on its concentration advantage, not merely cost or availability.
Option D: Option D is incorrect: ABO compatibility recommendations for cryoprecipitate vary by institution, and compatibility matching considerations apply to both products; the primary rationale for cryoprecipitate preference is its concentration advantage, not ABO compatibility.
Option E: Option E is incorrect: cryoprecipitate is not a recombinant product — it is a donor-derived blood component prepared from FFP; both cryoprecipitate and FFP carry comparable transfusion-transmitted infection risks.
8. An emergency physician is managing post-thrombolytic bleeding in a 67-year-old man who received alteplase for STEMI (ST-segment elevation myocardial infarction) and is now hemorrhaging from multiple sites. After stopping the alteplase infusion and ordering cryoprecipitate, she asks for an antifibrinolytic agent. The pharmacy stocks both tranexamic acid (TXA) and epsilon-aminocaproic acid (EACA). Which of the following correctly states the IV dosing regimen for each agent?
A) TXA: 1 g IV over 10 minutes followed by 1 g IV over 8 hours (the CRASH-2 trauma protocol); EACA: 10 g IV loading dose over 30 minutes followed by 2 g/hr continuous infusion
B) TXA: 25 mg/kg IV bolus over 5 minutes, no maintenance infusion required due to its 3-hour plasma half-life; EACA: 2.5 g IV bolus followed by 0.5 g/hr infusion, half the standard dose when used with concurrent cryoprecipitate
C) TXA: 500 mg IV bolus repeated every 8 hours for 24 hours; EACA: 5 g IV loading dose, then 500 mg IV every 6 hours as intermittent dosing rather than a continuous infusion
D) TXA and EACA are used at identical weight-based doses of 15 mg/kg IV for the loading dose; they differ only in maintenance: TXA requires no maintenance infusion whereas EACA requires 1 g/hr; both agents share a maximum total dose of 10 g in 24 hours
E) TXA: 10 to 15 mg/kg IV administered over 10 minutes; EACA: 5 g IV loading dose administered over 15 to 30 minutes followed by a continuous infusion of 1 to 1.25 g/hr; both agents are lysine analogues that block plasminogen kringle-domain binding sites and inhibit fibrinolysis by the same mechanism
ANSWER: E
Rationale:
Option E is correct. Tranexamic acid (TXA) and epsilon-aminocaproic acid (EACA) are both synthetic lysine analogues that share the same antifibrinolytic mechanism — competitive blockade of lysine-binding sites (kringle domains) in plasminogen, preventing plasminogen from binding fibrin and thereby inhibiting its activation to plasmin by tPA. They differ in potency (TXA is approximately 6 to 10 times more potent than EACA on a molar basis) and in dosing regimen. For post-thrombolytic bleeding: TXA is given as 10 to 15 mg/kg IV over 10 minutes as a single loading dose. EACA is given as a 5 g IV loading dose over 15 to 30 minutes followed by a continuous infusion of 1 to 1.25 g/hr. Either agent combined with cryoprecipitate and cessation of the thrombolytic constitutes the core pharmacological reversal strategy.
Option A: Option A is incorrect: the 1 g + 1 g over 8 hours TXA regimen is the CRASH-2 trauma hemorrhage protocol, which uses a lower dose than the thrombolytic reversal protocol; the EACA loading dose of 10 g is double the standard 5 g loading dose and is not a recognized regimen.
Option B: Option B is incorrect: the TXA dose of 25 mg/kg is above the standard post-thrombolytic reversal range; TXA's half-life does not eliminate the need for careful dosing in this setting, and the EACA dose of 2.5 g is half the standard loading dose.
Option C: Option C is incorrect: TXA is not given as repeated 500 mg boluses in this setting; EACA is standard as a continuous infusion, not as intermittent fixed doses every 6 hours.
Option D: Option D is incorrect: TXA and EACA are not used at identical weight-based doses — they differ in dosing regimen and potency, not merely in the presence or absence of a maintenance infusion; a 15 mg/kg loading dose for EACA is not the standard protocol.
9. A 71-year-old woman on warfarin for atrial fibrillation has a routine INR (international normalized ratio) check that returns at 7.4. She has no signs of bleeding. Her last dose of warfarin was this morning. She is otherwise well and hemodynamically stable. Which of the following represents the most appropriate vitamin K management for this degree of over-anticoagulation without active bleeding?
A) Administer IV vitamin K 10 mg over 30 minutes in the emergency department to achieve the most rapid possible INR reduction, as an INR above 5 carries sufficient spontaneous hemorrhage risk to justify intravenous rather than oral administration in all cases
B) Hold warfarin and administer oral vitamin K 2.5 to 5 mg; recheck the INR in 24 to 48 hours; resume warfarin at a lower dose once the INR is in the therapeutic range; oral vitamin K at this dose achieves INR correction within 24 to 48 hours with minimal anaphylaxis risk compared with IV administration
C) No vitamin K is needed; simply hold warfarin for 2 to 3 doses until the INR drifts back into range through natural factor resynthesis, as the risk of administering any dose of exogenous vitamin K outweighs the benefit when there is no active bleeding
D) Administer oral vitamin K 10 mg — the same dose used for urgent reversal — to ensure complete and rapid INR correction; higher oral doses produce faster INR normalization than lower doses and do not carry excess thrombosis risk in patients with atrial fibrillation
E) Administer IV vitamin K 2 to 4 mg and schedule the patient for same-day direct observation in the ED (emergency department) for 4 hours to monitor for anaphylaxis; this is the preferred approach for any INR above 5 regardless of clinical bleeding status
ANSWER: B
Rationale:
Option B is correct. For asymptomatic over-anticoagulation with INR in the range of approximately 4 to 10 and no active bleeding, current CHEST and AHA guidelines recommend holding warfarin and administering a low dose of oral vitamin K (2.5 to 5 mg). Oral vitamin K at this dose achieves clinically meaningful INR reduction within 24 to 48 hours through restoration of hepatic factor synthesis. The oral route is preferred over IV in non-urgent settings because IV vitamin K carries a small but real risk of anaphylaxis (estimated at approximately 1 in 10,000 doses when given rapidly) and is unnecessary when there is no hemodynamic urgency. Warfarin should be restarted at a reduced dose once the INR returns to the therapeutic range to avoid repeated supratherapeutic anticoagulation.
Option A: Option A is incorrect: IV vitamin K 10 mg is indicated for life-threatening or major bleeding requiring emergency reversal — not for asymptomatic over-anticoagulation without bleeding; using IV vitamin K routinely for any INR above 5 is not guideline-supported and exposes the patient to unnecessary anaphylaxis risk.
Option C: Option C is incorrect: holding warfarin alone (without any vitamin K) is an option only for mild over-anticoagulation (INR approximately 3 to 5) in patients at low bleeding risk; at INR 7.4, supplemental low-dose oral vitamin K is recommended to accelerate INR correction — relying on passive warfarin elimination alone is appropriate for lower INR elevations but not at this level.
Option D: Option D is incorrect: oral vitamin K 10 mg is a high dose that may overcorrect the INR into sub-therapeutic range and make re-anticoagulation more difficult; higher oral doses are appropriate for urgent reversal with major bleeding, not for asymptomatic over-anticoagulation.
Option E: Option E is incorrect: IV vitamin K 2 to 4 mg with ED observation is not the recommended protocol for asymptomatic over-anticoagulation; oral administration with outpatient follow-up is the standard approach when there is no active bleeding.
10. A 78-year-old woman on warfarin with a mechanical mitral valve presents with acute GI (gastrointestinal) hemorrhage and hemodynamic instability. Her INR is 8.9. Emergent reversal is required. Which of the following correctly identifies the 4F-PCC (four-factor prothrombin complex concentrate) dose for this INR level, explains why IV vitamin K must be co-administered, and states the volume advantage over FFP (fresh frozen plasma)?
A) 4F-PCC 25 units/kg (maximum 2,500 units) for INR 8.9, which falls in the INR 6 to 10 dosing tier; IV vitamin K is added because 4F-PCC contains no vitamin K and factor resynthesis must be independently stimulated; 4F-PCC is administered in approximately 100 to 250 mL versus 4 to 6 units of FFP (approximately 1,000 to 1,500 mL)
B) 4F-PCC 35 units/kg (maximum 3,500 units) for INR 8.9, which falls within the INR 4 to 6 dosing tier; vitamin K is co-administered to prevent rebound anticoagulation; 4F-PCC achieves INR correction within 15 to 30 minutes versus 30 to 60 minutes for FFP after thawing
C) 4F-PCC 50 units/kg (maximum 5,000 units) for INR above 6; IV vitamin K 10 mg must be co-administered simultaneously because 4F-PCC factors are cleared within approximately 6 to 24 hours and without sustained vitamin K-driven factor synthesis the INR will rebound as warfarin continues to suppress endogenous factor production; 4F-PCC achieves INR correction within 15 to 30 minutes in a volume of approximately 100 to 250 mL
D) 4F-PCC 50 units/kg for INR above 6; IV vitamin K is administered 6 hours after 4F-PCC to allow the concentrate to fully equilibrate before introducing competitive factor regeneration; the delayed vitamin K approach reduces the risk of thrombotic complications from simultaneous procoagulant loading
E) 4F-PCC dose is fixed at 1,500 units regardless of INR or body weight for all emergent VKA (vitamin K antagonist) reversals, as weight-based dosing has been shown to increase thrombotic complications without improving INR correction speed; vitamin K is added only if the INR remains above 2.0 at 30 minutes
ANSWER: C
Rationale:
Option C is correct. The weight-based and INR-tiered dosing for 4F-PCC (Kcentra) is: INR 2 to 3.9 — 25 units/kg (maximum 2,500 units); INR 4 to 6 — 35 units/kg (maximum 3,500 units); INR above 6 — 50 units/kg (maximum 5,000 units). This patient's INR of 8.9 falls in the above-6 tier, requiring 50 units/kg (maximum 5,000 units). IV vitamin K 10 mg must be co-administered simultaneously — not afterward — because 4F-PCC provides immediate factor replacement but the infused factors are cleared over the following 6 to 24 hours (depending on individual factor half-lives: factor VII approximately 4 to 6 hours, factor II approximately 60 to 72 hours). Without concurrent vitamin K to restore endogenous factor synthesis, the INR will rebound as PCC factors clear and warfarin continues to suppress new factor production. 4F-PCC achieves INR correction within 15 to 30 minutes in a small administered volume (approximately 100 to 250 mL), compared with the 4 to 6 units of FFP (approximately 1,000 to 1,500 mL) that would otherwise be required, with associated fluid overload and TRALI risks eliminated.
Option A: Option A is incorrect: 25 units/kg is the dose for INR 2 to 3.9, not INR above 6; for INR 8.9 this underdoses by half and will not achieve adequate INR correction.
Option B: Option B is incorrect: 35 units/kg is the dose for INR 4 to 6; INR 8.9 requires the highest dose tier of 50 units/kg.
Option D: Option D is incorrect: IV vitamin K must be administered simultaneously with 4F-PCC, not 6 hours afterward; delaying vitamin K allows factor levels to fall as PCC is cleared before new synthesis is stimulated, creating a window of re-anticoagulation; co-administration is the standard protocol.
Option E: Option E is incorrect: 4F-PCC dosing is weight-based and INR-tiered per the FDA-approved label; a fixed 1,500-unit dose is not a recognized dosing protocol and would substantially underdose most patients at high INR levels.
11. A 74-year-old man taking rivaroxaban 20 mg daily for atrial fibrillation presents with a major GI (gastrointestinal) bleed. His last dose was taken approximately 10 hours ago. Andexanet alfa is available. The pharmacist asks which dosing regimen — low or high — is appropriate. Which of the following correctly states the criteria distinguishing andexanet's low-dose from high-dose regimen, and identifies the correct regimen for this patient?
A) The low-dose regimen (400 mg IV bolus followed by 480 mg over 2 hours) is used for any factor Xa inhibitor taken more than 4 hours before treatment regardless of dose; because this patient took rivaroxaban 10 hours ago, the low-dose regimen applies
B) The high-dose regimen (800 mg IV bolus followed by 960 mg over 2 hours) is always used for rivaroxaban regardless of dose or timing, because rivaroxaban has higher anti-Xa potency per milligram than apixaban and requires the larger reversal dose in all clinical scenarios
C) The low-dose regimen applies when the patient is on apixaban at any dose and the high-dose regimen applies exclusively to rivaroxaban and edoxaban regardless of timing, reflecting the higher total daily drug burden of rivaroxaban compared with apixaban
D) The low-dose regimen (400 mg IV bolus followed by 480 mg over 2 hours) applies to rivaroxaban 10 mg or less, apixaban 5 mg or less, or any dose of either drug taken more than 8 hours before treatment; the high-dose regimen (800 mg IV bolus followed by 960 mg over 2 hours) applies to rivaroxaban above 10 mg, apixaban above 5 mg, or edoxaban taken within 8 hours; this patient on rivaroxaban 20 mg taken 10 hours ago meets the low-dose criterion (last dose more than 8 hours before treatment)
E) High-dose andexanet is required whenever the presenting anti-Xa level exceeds 0.5 IU/mL regardless of which agent or dose was taken; low-dose is reserved for patients with anti-Xa levels below this threshold; laboratory measurement is therefore required before dosing andexanet in all cases
ANSWER: D
Rationale:
Option D is correct. Andexanet alfa dosing is determined by three criteria: the specific agent, the dose, and the time since the last dose. The low-dose regimen (400 mg IV bolus followed by 480 mg IV over 2 hours) is used when the patient is taking rivaroxaban 10 mg or less, apixaban 5 mg or less, or when the last dose of any factor Xa inhibitor was taken more than 8 hours before andexanet administration. The high-dose regimen (800 mg IV bolus followed by 960 mg IV over 2 hours) is used when the patient is taking rivaroxaban above 10 mg, apixaban above 5 mg, or edoxaban taken within 8 hours. This patient took rivaroxaban 20 mg — which normally falls in the high-dose category — but took it 10 hours ago; because the last dose was more than 8 hours before treatment, the low-dose regimen applies. Andexanet is not approved for fondaparinux reversal.
Option A: Option A is incorrect: the time-based cutoff is more than 8 hours, not more than 4 hours; using a 4-hour threshold would incorrectly assign low-dose status to patients with more recently administered higher doses.
Option B: Option B is incorrect: rivaroxaban does not always require the high-dose regimen — for rivaroxaban 10 mg or less, or any rivaroxaban taken more than 8 hours before treatment, the low-dose regimen applies; dose and timing jointly determine regimen selection.
Option C: Option C is incorrect: the regimen selection is not based on the specific drug (rivaroxaban vs. apixaban) alone — it depends on the dose of that specific drug and the timing; apixaban above 5 mg within 8 hours requires the high-dose regimen.
Option E: Option E is incorrect: andexanet dosing is not determined by anti-Xa level measurement in clinical practice; the prescribing information specifies dosing by agent, dose tier, and time since last dose — laboratory anti-Xa measurement is not required for dosing determination.
12. A 68-year-old woman on apixaban for atrial fibrillation presents to the emergency department after an intentional ingestion of her entire monthly supply of apixaban tablets approximately 90 minutes ago. She has no active bleeding. Idarucizumab is on the formulary but she is on apixaban not dabigatran. Andexanet alfa is not available at this facility. Which of the following correctly identifies the role of activated charcoal in this clinical scenario and its timing requirement?
A) Activated charcoal is contraindicated in DOAC (direct oral anticoagulant) overdose because it adsorbs vitamin K from the gastrointestinal tract, worsening coagulopathy by depleting the substrate needed for factor synthesis
B) Activated charcoal is effective for DOAC adsorption regardless of ingestion timing because DOACs undergo extensive enterohepatic recirculation; repeated doses of activated charcoal over 24 hours are therefore recommended for all DOAC overdoses to interrupt the recirculation cycle
C) Activated charcoal 50 g orally can reduce gut absorption of DOACs if administered within approximately 2 to 4 hours of ingestion; beyond this window, most of the drug has already been absorbed from the GI (gastrointestinal) tract and activated charcoal provides no meaningful benefit; at 90 minutes post-ingestion, activated charcoal should be administered promptly
D) Activated charcoal must be given within 30 minutes of DOAC ingestion to be effective; at 90 minutes post-ingestion it is too late to provide meaningful GI desorption, and the clinical team should proceed directly to 4F-PCC (four-factor prothrombin complex concentrate) infusion
E) Activated charcoal is effective for rivaroxaban and edoxaban overdose but not for apixaban, because apixaban's high protein binding (approximately 87%) prevents its adsorption by activated charcoal in the gastrointestinal lumen; protein-bound drug cannot be captured by charcoal before absorption
ANSWER: C
Rationale:
Option C is correct. Activated charcoal (50 g orally or via nasogastric tube) can adsorb DOACs within the gastrointestinal tract before absorption is complete, reducing peak plasma drug concentration and total systemic exposure. The effectiveness of activated charcoal is time-dependent: it is most effective when given within 1 to 2 hours of ingestion and retains meaningful benefit up to approximately 2 to 4 hours post-ingestion. Beyond this window, most of the drug has been absorbed from the small intestine and activated charcoal in the GI lumen can no longer intercept significant drug mass. This patient ingested apixaban approximately 90 minutes ago — within the 2 to 4 hour window — and activated charcoal should be administered promptly. In the absence of andexanet alfa, 4F-PCC at 50 units/kg is the best available non-specific alternative if bleeding develops.
Option A: Option A is incorrect: activated charcoal does not deplete dietary vitamin K and does not worsen DOAC coagulopathy through vitamin K depletion; DOACs do not work through the vitamin K pathway, and activated charcoal's mechanism of GI adsorption is not selective for vitamin K.
Option B: Option B is incorrect: apixaban, rivaroxaban, and other DOACs do not undergo significant enterohepatic recirculation (unlike some other drugs); repeated-dose activated charcoal for enterohepatic interruption is not a recognized or effective strategy for DOAC overdose management.
Option D: Option D is incorrect: the effective window for activated charcoal is approximately 2 to 4 hours from ingestion, not 30 minutes; at 90 minutes the patient is clearly within the effective window and activated charcoal is appropriate.
Option E: Option E is incorrect: activated charcoal adsorbs drugs within the gastrointestinal lumen before they are absorbed into the bloodstream; protein binding is irrelevant to this process because the drug has not yet been absorbed and is not yet protein-bound in plasma at the time activated charcoal acts in the gut.
13. A 76-year-old man with stage 3 CKD (chronic kidney disease, creatinine clearance 32 mL/min) and atrial fibrillation on dabigatran presents with a serious GI (gastrointestinal) bleed. Idarucizumab 5 g IV is administered and achieves complete reversal of dabigatran anticoagulation as confirmed by normalization of the dilute thrombin time. Sixteen hours later, routine lab work shows re-elevation of the dilute thrombin time consistent with renewed dabigatran anticoagulant activity. Which of the following best explains this phenomenon and identifies the appropriate management?
A) Idarucizumab undergoes incomplete dabigatran binding at standard doses in patients with renal impairment because reduced renal clearance of the idarucizumab-dabigatran complex prolongs its residence in plasma and allows competitive displacement of dabigatran back into free circulation; a second dose doubles the complex clearance rate
B) Rebound dabigatran anticoagulation occurs because dabigatran is distributed into tissue compartments and bound to plasma proteins at the time of idarucizumab administration; as idarucizumab is cleared from the circulation (half-life approximately 45 minutes), dabigatran sequestered in tissues and protein-bound dabigatran redistribute back into plasma — this redistribution is more pronounced in patients with renal impairment because reduced renal clearance prolongs dabigatran's overall body burden; a second 5 g dose of idarucizumab can be administered if clinically significant rebound occurs
C) Rebound anticoagulation after idarucizumab represents failure of the first dose due to subtherapeutic drug concentration from errors in preparation or administration; the standard protocol requires fresh idarucizumab from a new vial because the drug degrades within 4 hours of reconstitution at room temperature
D) Renewed anticoagulant activity at 16 hours indicates that the patient has been re-dosed with dabigatran by nursing staff; idarucizumab has a sustained effect lasting 24 to 48 hours that cannot be overcome by a single dabigatran dose, so renewed anticoagulation within this window must represent exogenous re-administration
E) Rebound anticoagulation is an expected pharmacokinetic phenomenon that occurs with all DOAC reversal agents including andexanet alfa and idarucizumab, reflecting the equal redistribution rates of all DOACs from tissue and protein-bound compartments back into plasma after reversal agent clearance; no additional intervention is required unless bleeding recurs
ANSWER: B
Rationale:
Option B is correct. Rebound dabigatran anticoagulation after idarucizumab is a recognized clinical phenomenon, particularly in patients with renal impairment. When idarucizumab is administered, it captures circulating free dabigatran into an inactive complex. However, not all dabigatran in the body is immediately available in the free plasma compartment: some is distributed into tissue compartments and some is loosely protein-bound. As idarucizumab is cleared renally (half-life approximately 45 minutes), the idarucizumab-dabigatran complex is excreted in urine. Once idarucizumab is eliminated, dabigatran sequestered in tissues gradually redistributes back into plasma — re-establishing anticoagulant activity. In patients with renal impairment (such as this patient with CrCl 32 mL/min), dabigatran clearance is substantially reduced (dabigatran is approximately 80% renally eliminated), leading to higher total body drug burden and more pronounced redistribution. The RE-VERSE AD trial observed rebound in a subset of patients, particularly those with renal impairment. A second 5 g dose of idarucizumab can be administered if rebound is associated with clinically significant anticoagulation and active or new bleeding.
Option A: Option A is incorrect: idarucizumab binding affinity for dabigatran is approximately 350-fold greater than dabigatran's affinity for thrombin — competitive displacement of dabigatran from idarucizumab in plasma does not occur; the rebound is due to tissue redistribution of dabigatran, not competitive binding kinetics within the idarucizumab-dabigatran complex.
Option C: Option C is incorrect: idarucizumab does not fail due to drug degradation in clinical use within 16 hours; the observed rebound is a predictable pharmacokinetic phenomenon explained by tissue redistribution, not a preparation error.
Option D: Option D is incorrect: rebound anticoagulation in this setting reflects pharmacokinetic redistribution, not re-administration; idarucizumab does not have a 24 to 48 hour sustained protective window that would prevent any response to a new dabigatran dose — the drug is cleared within hours.
Option E: Option E is incorrect: rebound anticoagulation is specifically described for dabigatran-idarucizumab rather than being a universal phenomenon equally affecting all DOAC reversal agents; andexanet alfa has its own rebound phenomenon related to redistribution of factor Xa inhibitors, but the mechanism and degree differ; characterizing this as uniform across all agents requiring no intervention is clinically inaccurate.
14. A 64-year-old man with type 1 diabetes on NPH (neutral protamine Hagedorn) insulin is undergoing cardiac surgery on cardiopulmonary bypass. At the conclusion of the procedure, protamine sulfate is administered for heparin reversal. Within 2 minutes of the protamine infusion, the patient develops hypotension (BP 72/40 mmHg), bradycardia (HR 42 bpm), and a rise in pulmonary artery pressure from 22 to 46 mmHg. Which of the following correctly explains this adverse event profile and its mechanistic basis, including the relevance of this patient's insulin regimen?
A) This presentation — bradycardia, hypotension, and elevated pulmonary artery pressure — represents a protamine adverse reaction mediated through multiple mechanisms: histamine release from mast cells and basophils causes vasodilation and bradycardia; complement activation via the alternative pathway contributes to pulmonary vasoconstriction and elevated pulmonary artery pressure; patients previously exposed to protamine through NPH (neutral protamine Hagedorn) insulin — which contains protamine as a carrier protein for the insulin crystals — are at increased risk for anaphylactic and anaphylactoid reactions because prior sensitization has generated anti-protamine antibodies
B) This presentation represents warfarin-induced coagulopathy triggered by heparin neutralization; protamine competitively displaces warfarin from albumin binding sites, releasing free warfarin that suppresses vitamin K-dependent factor synthesis rapidly, causing hemodynamic collapse through acute procoagulant-anticoagulant imbalance
C) This presentation reflects protamine's direct positive chronotropic and vasodilatory effects at high plasma concentrations; the pulmonary hypertension is caused by protamine-induced platelet aggregation in the pulmonary vasculature, forming microemboli that obstruct pulmonary flow; NPH insulin exposure is irrelevant because the protamine in NPH is in a non-sensitizing crystalline form
D) This is an expected pharmacodynamic response to complete heparin neutralization — removal of heparin's vasodilatory and heart-rate-lowering effects causes a rebound increase in sympathetic vascular tone, bradycardia from vagal reflex, and reactive pulmonary hypertension from previously suppressed hypoxic vasoconstriction; no specific treatment beyond observation is required
E) This presentation represents heparin-protamine complex precipitation in the pulmonary microvasculature, causing mechanical obstruction and right heart strain; bradycardia results from vagal stimulation by acute right ventricular distension; the correct management is immediate re-administration of heparin to dissolve the precipitated complexes
ANSWER: A
Rationale:
Option A is correct. Protamine adverse reactions encompass several overlapping mechanisms: (1) histamine release from mast cells and basophils — mediated by both IgE-dependent (anaphylactic) and IgE-independent (anaphylactoid) pathways — causing systemic vasodilation, hypotension, and bradycardia; (2) complement activation via the alternative or classical pathway, triggering pulmonary vasoconstriction and elevated pulmonary artery pressure through thromboxane A2 and leukotriene release from activated platelets and leukocytes; and (3) direct cardiac depression at high doses. Prior protamine exposure is the key risk factor: patients who have used NPH insulin are sensitized to protamine because NPH insulin suspensions contain protamine as the carrier protein that complexes with insulin to retard absorption. This prior exposure generates anti-protamine antibodies that can trigger a severe anaphylactic reaction upon protamine re-exposure. Other risk factors include prior protamine administration for a previous procedure and fish (salmon) allergy, as protamine is derived from salmon sperm. The maximum recommended infusion rate is 5 mg/min (maximum 50 mg over 10 minutes) to reduce the rate of adverse reactions.
Option B: Option B is incorrect: protamine does not interact with warfarin or displace it from albumin binding sites; protamine reverses heparin through ionic neutralization, an entirely separate mechanism from VKA pharmacology.
Option C: Option C is incorrect: protamine does not have positive chronotropic effects — it causes bradycardia through histamine release; NPH insulin exposure is highly relevant as a sensitizing prior exposure, not irrelevant.
Option D: Option D is incorrect: the described hemodynamic changes are not expected pharmacodynamic consequences of heparin neutralization; they represent an adverse drug reaction requiring active management, not observation alone.
Option E: Option E is incorrect: while heparin-protamine complexes do form, they are cleared by the reticuloendothelial system rather than precipitating as pulmonary emboli; re-administering heparin to dissolve the complexes would be dangerous and re-anticoagulate the post-operative patient.
15. A 59-year-old man with acute anterior STEMI (ST-segment elevation myocardial infarction) at a hospital without PCI (percutaneous coronary intervention) capability receives tenecteplase and achieves successful reperfusion (greater than 50% ST resolution at 60 minutes). The team is planning adjunctive anticoagulation. The patient is 70 kg and has a CrCl (creatinine clearance) of 68 mL/min. Which of the following correctly identifies the preferred anticoagulant regimen for post-fibrinolysis STEMI management, including dose and minimum duration?
A) UFH (unfractionated heparin) 60 units/kg IV bolus (maximum 4,000 units) followed by 12 units/kg/hr (maximum 1,000 units/hr) adjusted to aPTT (activated partial thromboplastin time) 50 to 70 seconds is the preferred agent after fibrinolysis because its reversibility with protamine makes it safer than LMWH in the post-thrombolytic setting where rapid anticoagulant reversal may be required; minimum duration is 24 hours
B) Fondaparinux 2.5 mg SC (subcutaneous) once daily is the preferred agent after fibrinolysis regardless of renal function because it has the lowest bleeding risk of any anticoagulant in post-thrombolytic STEMI; it is preferred over enoxaparin for both early-invasive and non-invasive management strategies
C) Bivalirudin, a direct thrombin inhibitor, is the preferred anticoagulant after fibrinolysis for STEMI because it does not require anti-Xa or aPTT monitoring and has a predictable effect; it is given as a continuous IV infusion of 0.25 mg/kg/hr for at least 48 hours
D) Anticoagulation is not required after successful fibrinolysis — once ST resolution exceeds 50% at 60 minutes the infarct artery is confirmed open and anticoagulant therapy carries more bleeding risk than benefit; early PCI consultation is the only indicated intervention after successful reperfusion
E) Enoxaparin is the preferred anticoagulant after fibrinolysis for STEMI, supported by the ExTRACT-TIMI 25 trial demonstrating superiority over UFH; the dose for this patient is 30 mg IV bolus followed by 1 mg/kg SC every 12 hours; anticoagulation must be continued for a minimum of 48 hours or until revascularization (whichever comes first)
ANSWER: E
Rationale:
Option E is correct. Post-fibrinolysis anticoagulation in STEMI is required to prevent reocclusion of the infarct-related artery and to support the pharmacoinvasive strategy (early coronary angiography at 3 to 24 hours). Enoxaparin is preferred over UFH based on the ExTRACT-TIMI 25 trial (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment), which demonstrated that enoxaparin significantly reduced the composite of death or nonfatal MI at 30 days compared with UFH in post-fibrinolysis STEMI, despite a modest increase in non-intracranial major bleeding. The standard dose for patients under 75 years with CrCl above 30 mL/min is a 30 mg IV bolus followed by 1 mg/kg SC every 12 hours — for this 70 kg patient, 70 mg SC every 12 hours after the bolus. Anticoagulation must continue for at least 48 hours or until revascularization.
Option A: Option A is incorrect: while UFH is an acceptable alternative when enoxaparin is unavailable, enoxaparin is the preferred agent per guidelines based on ExTRACT-TIMI 25 superiority data; describing UFH as preferred is inconsistent with current evidence and guidelines.
Option B: Option B is incorrect: fondaparinux 2.5 mg SC once daily is an option for patients not receiving early invasive management, but it is not preferred over enoxaparin for all post-fibrinolysis STEMI management; fondaparinux cannot be used as the sole anticoagulant in patients undergoing PCI (it requires UFH supplementation to avoid catheter thrombosis due to its lack of anti-IIa activity).
Option C: Option C is incorrect: bivalirudin is used as a procedural anticoagulant during PCI but is not an established standard post-fibrinolysis anticoagulation agent for STEMI; there is no approved or guideline-endorsed role for bivalirudin as 48-hour infusion after fibrinolysis.
Option D: Option D is incorrect: post-fibrinolysis anticoagulation is mandatory and evidence-based; withholding anticoagulation after successful reperfusion would leave the patient at high risk for reocclusion, recurrent MI, and thrombotic complications; anticoagulation for at least 48 hours is standard of care.
16. A 28-year-old man with newly diagnosed APL (acute promyelocytic leukemia) presents with severe bleeding from IV sites, gums, and petechiae. Laboratory results confirm DIC (disseminated intravascular coagulation) with markedly elevated D-dimer, low fibrinogen, and prolonged PT/aPTT. His hematologist notes that this patient's bleeding is driven predominantly by primary hyperfibrinolysis rather than the consumptive coagulopathy pattern typical of sepsis-associated DIC, and considers tranexamic acid (TXA). Which of the following correctly explains why TXA is appropriate in APL-associated DIC but contraindicated in most other forms of DIC?
A) TXA is appropriate in APL because APL blasts express tissue factor constitutively, activating the extrinsic coagulation pathway; TXA's thrombin-inhibiting properties counteract this tissue factor-driven coagulation, whereas in other forms of DIC thrombin generation is already depressed and TXA would worsen hypocoagulability
B) TXA is appropriate in APL because ATRA (all-trans retinoic acid) treatment causes paradoxical fibrinogen consumption as it differentiates APL blasts; TXA prevents this ATRA-induced fibrinogenolysis and must be co-administered with ATRA from the first dose; in other DIC forms TXA is avoided because it is metabolized by the same enzyme pathway that activates ATRA, creating a drug interaction
C) TXA is appropriate in APL because leukemic promyelocytes express high levels of CD56, which activates plasminogen to plasmin independently of tPA; TXA blocks this CD56-mediated plasmin generation, whereas in other DIC forms plasmin is generated via tPA and TXA has no efficacy against this pathway
D) In APL, leukemic promyelocytes release annexin II (which dramatically upregulates tPA activity) and express membrane-bound plasminogen activators, creating a primary hyperfibrinolytic state in which plasmin generation exceeds and precedes the consumptive coagulopathy; suppressing this fibrinolysis with TXA is beneficial and does not risk worsening microvascular thrombosis because the net coagulation state is hypofibrinolytic; in other forms of DIC, fibrinolysis is reactive and protective against microvascular occlusion, so TXA suppression risks extending ischemic organ damage
E) TXA is appropriate in APL only after ATRA has been administered for at least 72 hours, because ATRA must first differentiate the promyelocytes sufficiently to eliminate their plasminogen activator expression before TXA is safe; using TXA before 72 hours of ATRA creates a thrombotic storm by eliminating fibrinolysis in a patient with active DIC-driven microvascular thrombosis
ANSWER: D
Rationale:
Option D is correct. APL (acute promyelocytic leukemia) is unique among hematological malignancies in that the malignant promyelocytes express and release large quantities of annexin II — a cell surface protein that acts as a co-receptor for both tPA and plasminogen, dramatically amplifying tPA-driven plasmin generation at the promyelocyte surface. Additionally, APL promyelocytes express membrane-bound urokinase-type plasminogen activator (uPA). This creates a state of primary hyperfibrinolysis — meaning plasmin generation is the primary event, driving fibrinogen consumption and severe bleeding rather than occurring secondarily to thrombin-driven coagulation activation. In this primary hyperfibrinolytic state, suppressing fibrinolysis with TXA reduces pathological bleeding without the risk of extending microvascular thrombosis, because the predominant net coagulation defect is fibrinolytic rather than procoagulant. TXA is given as a bridge until ATRA (all-trans retinoic acid) differentiates the promyelocytes and eliminates the hyperfibrinolytic stimulus. In other DIC forms (sepsis, trauma, obstetric emergencies), fibrinolysis is reactive — it is upregulated in response to microvascular fibrin deposition and protects against organ ischemia by lysing pathological microthrombi; suppressing it with TXA can extend microvascular occlusion and worsen multiorgan failure.
Option A: Option A is incorrect: TXA is a lysine analogue antifibrinolytic — it does not inhibit thrombin and has no anti-thrombin-inhibiting mechanism; describing TXA as counteracting tissue factor-driven coagulation is mechanistically wrong.
Option B: Option B is incorrect: ATRA does not cause paradoxical fibrinogenolysis — it promotes differentiation of promyelocytes, which reduces (not increases) the hyperfibrinolytic stimulus; there is no clinically relevant pharmacokinetic interaction between TXA and ATRA.
Option C: Option C is incorrect: CD56 is an adhesion molecule expressed on some APL blasts but is not a plasminogen activator; the hyperfibrinolytic mechanism in APL is annexin II and uPA-mediated, not CD56-mediated.
Option E: Option E is incorrect: the current standard of care in APL-associated DIC with bleeding includes TXA from the time of diagnosis, not after a 72-hour ATRA delay; waiting 72 hours before giving TXA would leave the patient hemorrhaging from severe primary hyperfibrinolysis during the most dangerous period of their disease course.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.